Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
China Pharmacy ; (12): 2736-2740, 2020.
Artigo em Chinês | WPRIM | ID: wpr-829975

RESUMO

OBJECTIVE:To evaluate the effects of nicorand il on the proliferation ,migration ability and Hippo/YAP signaling pathway of pulmonary artery smooth muscle cells (PASMCs). METHODS :Human primary PASMCs were divided into normal control group ,model group ,nicorandil low ,medium and high concentration groups (50,100,200 μmol/L),with 3 holes in each group. In addition to the normal control group ,the rest of the cells were inoculated on the gel coated medium to simulate the pulmonary hypertension environment ,so as to establish AS cell model. Then ,each drug group was added with corresponding drugs,and the normal control group and model group were added with the same volume of normal saline ,and cultured for 48 h. CCK-8 assay and Transwell assay were used for the examination of cell proliferation (by light density )and migration ability , respectively. mRNA expression of YAP target factors (CTGF and AREG )were examined by qRT-PCR. Western blotting assay was used to detect the protein expression of CTGF and AREG. RESULTS :Compared with normal control group ,light density of cells was increased significantly in model group ;the number of migration cells per field of view increased significantly ;mRNA and protein expression of CTGF and AREG were significantly increased (P<0.01). Compared with model group ,light density ,the number of migration cells per field of view ,mRNA and protein expression of CTGF and AREG in nicorandil low ,medium and high concentration groups were decreased significantly , in concentration-dependent manner (P<0.05 or P<0.01). CONCLUSIONS:Nicorandil can inhibit the proliferation and migration of PASMCs in AS model ,the mechanism of which cstc2019jscx-msxmX0174) may be associated with the Hippo/YAP signaling pathway.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA